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Abstract
Previous research has shown that fibroblast growth factor 2 protein (FGF2) can act as an
anxiolytic and anti-depressive agent in rodents. Levels of hippocampal FGF2 and FGF2
receptors are decreased in post-mortem brains of individuals with mood disorders. No
changes in FGF2 were noted in the post-mortem brains of individuals with mood disorders
that were successfully treated with anti-depressant medication prior to death. Mutations in
the FGF2 gene in humans have been shown to predict non-responsiveness to the therapeu-
tic effects of selective serotonin reuptake inhibitors (SSRIs). These findings suggest that
FGF2 may potentially be a target of and/or required for the therapeutic effects of antidepres-
sant medications. To test this, we employed a rodent model of depressive behaviour,
chronic variable stress (CVS) in conjunction with antidepressant treatment (fluoxetine) in
wild-type (WT) and FGF2 knockout mice (FGF2KO) and examined depressive and anxiety
behaviors. Results showed that fluoxetine reversed the effects of CVS on depressive and
anxiety behaviours in wild-type mice only, suggesting that the FGF2 gene is indeed neces-
sary for the therapeutic effects of fluoxetine. Interestingly, CVS decreased hippocampal
FGF2 levels and fluoxetine partially reversed this effect. Because FGF2 has been previously
shown to modify HPA activity through hippocampal glucocorticoid receptors (GR), we exam-
ined levels of glucocorticoid receptors and found a decrease in GR in response to CVS, with
a further decrease in FGF2KO. No effect of fluoxetine on GR was observed in either WT or
FGF2KO mice. This suggests that further changes in glucocorticoid receptors are not nec-
essary for the anti-depressant effects of fluoxetine in WT mice, although decreased gluco-
corticoid receptors in response to FGF2 deletion may preclude the therapeutic actions of
fluoxetine in FGF2KO. Whether astroglia, astroglial functions, or HPA changes are the
downstream target of FGF2-mediated changes induced by fluoxetine remains to be deter-
mined, however, the current study reaffirms the potential of FGF2 as a novel therapeutic tar-
get in the treatment of depression and anxiety disorders.
PLOS ONE | https://doi.org/10.1371/journal.pone.0204980 October 1, 2018 1 / 16
a1111111111
a1111111111
a1111111111
a1111111111
a1111111111
OPENACCESS
Citation: Simard S, Shail P, MacGregor J, El Sayed
M, Duman RS, Vaccarino F.M, et al. (2018)
Fibroblast growth factor 2 is necessary for
the antidepressant effects of fluoxetine. PLoS ONE
13(10): e0204980. https://doi.org/10.1371/journal.
pone.0204980
Editor: Judith Homberg, Radboud University
Medical Centre, NETHERLANDS
Received: July 30, 2018
Accepted: September 18, 2018
Published: October 1, 2018
Copyright: © 2018 Simard et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: All relevant data are
within the manuscript and its Supporting
Information files.
Funding: This work was supported by Canadian
Institute of Health Research Canada Research
Chair Award to N.S.; Canadian Funds for Innovation
to N.S.; Ontario Small Infrastructure award to N.S.;
Carleton University iCUREUS award to J.M.
Competing interests: The authors have declared
that no competing interests exist.
Introduction
Mood and anxiety disorders currently are the most prevalent mental illnesses diagnosed in
North America and have far-reaching effects on family and community function, as well as
gastrointestinal, respiratory and cardiovascular diseases [1, 2]. While distinct, depressive and
anxiety disorders have several overlapping symptoms and are often co-morbid. As such, cur-
rent treatments are often similar for both disorders and range from cognitive-behavioral psy-
chotherapy to antidepressant drugs such as selective serotonin reuptake inhibitors (SSRIs).
Unfortunately, these treatments are effective in just over half of diagnosed individuals, leaving
a considerable population treatment-resistant. A great deal of research has therefore focused
on understanding the neurobiological mechanisms that underlie the psychopathology of
depression and anxiety to elucidate novel therapeutic targets. Despite important recent devel-
opments such as the use of ketamine for intractable depression, the molecular basis of the etiol-
ogy and treatment of depression remains largely unknown.
Fibroblast growth factor 2 (FGF2) is a potent astroglial mitogen which is not only critical
during development, but is one of few growth factors (along with brain derived nerve factor
BDNF) that remain upregulated in the adult brain [3, 4]. As such, FGF2 plays a large role in
the response to injury in the adult brain and neuroplastic events such as postnatal neurogen-
esis [5], dendritic plasticity and long-term potentiation [6–9]. More recently, FGF2 has also
been implicated in anxiety and depressive behaviors, both in rodent models and in human
studies [10–18]. Work from the Akil laboratory demonstrated that FGF2 shows anxiolytic
properties in rats bred for high- anxiety and we have previously shown that depletion of the
FGF2 gene increases anxiety behavior and HPA activity [11–13]. Furthermore, we demon-
strated that FGF2-induced changes in HPA activity were necessary for the anxiolytic effects of
FGF2 [12]. In humans, FGF2 and FGF receptor levels are downregulated in post-mortem tis-
sue of individuals that had a history of mood disorders. Furthermore, no changes in FGF2
were noted in the post-mortem brains of individuals with mood disorders that were success-
fully treated with anti-depressant medication prior to death [14, 15, 18, 19].
In addition to a role for FGF2 in the display of depressive and anxiety behaviors, several
studies have linked FGF2 to the therapeutic effects of anti-depressant treatments such as SSRIs
[20]. Central FGF2 levels increase in response to SSRI treatment in rodents [21, 22], and, in
humans, mutations in the FGF2 gene predict responsivity to SSRI treatment [23]. Importantly,
these studies are mainly correlational in nature, therefore in the current study we examined
whether the FGF2 gene was necessary for the antidepressant effects of fluoxetine.
Methods
Experimental animals and procedure
Sixty-seven adult male FGF2 homozygous knockout (FGF2KO) and wildtype (WT) control
mice (Black Swiss background; Jackson Laboratory STOCK Fgf2tm1Doe/J), were bred by
establishing heterozygous breeding pairs. Wildtype control mice were comprised of 20 WT lit-
ter mates and 30 WT mice from the same background that were ordered from Charles River,
Canada, and used as controls distributed across groups. Mice were single housed in standard
(27cm X 17cm X 13cm), fully transparent polypropylene cages. Mice were genotyped using
the primers and PCR amplification protocol as recommended by JAX (https://www2.jax.org/
protocolsdb/f?p=116:5:0::NO:5:P5_MASTER_PROTOCOL_ID,P5_JRS_
CODE:22270,003256). All stress mice were placed in an isolated stress room for a period of
five weeks, with basic cage environment provided (nesting material and shelter). Mice were
maintained on a 12-hour light/dark cycle at 21˚C with ad lib food and water unless a particular
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stressor required otherwise (see below). Six groups were used in total; see Table 1 for further
breakdown. All animal use procedures were approved by the Carleton University Committee
for Animal Care, according to the guidelines set by the Canadian Council for the Use and Care
of Animals in Research.
Pilot study. 13 (7 Vehicle, 6 Fluoxetine) WT and 8 FGF2KO (4 Vehicle, 4 Fluoxetine)
were singly housed and maintained on a 12-hour light/dark cycle at 21˚C with ad lib food and
water. Behavioral results from vehicle-injected mice only were reported in a previous publica-
tion [12]. All mice received daily injections of either vehicle or fluoxetine (Prozac, Sigma-
Aldrich, 10mg/kg) for three weeks prior to behavior testing.
Chronic variable stress (CVS)
This experiment used a CVS paradigm adapted from the Duman laboratory to induce a
depressive and anxiety-like behavioral phenotype. An experimental timeline is shown in
Fig 1A. All animals were exposed to various mild stressors daily over 35 days (2–3 per 24-hour
period) that were uncontrollable in both time and duration to prevent habituation. Stressors
consisted of the following conditions: altered light/dark cycle, food and water deprivation
(overnight), isolation, cage tilt (30 degrees), exposure to odor, soiled bedding (~200 ml water
added to bedding material), no bedding, swim for 10 minutes and lastly, restraint (for 15 min-
utes, in restraint cones that have an opening in the front for ventilation). Animals were moni-
tored both during and immediately after each procedure. See Table 2 for an approximate
breakdown of the daily stressors and duration.
Antidepressant treatment and injection protocol
During the final three weeks of stress, half of the mice received the antidepressant treatment
fluoxetine. All mice received intraperitoneal injections of either vehicle (sterile saline, VWR
Canada) or fluoxetine (Prozac, Sigma-Aldrich, dose of 10mg/kg, dissolved in sterile saline at a
concentration of 2mg/ml) daily for the final three weeks of the experiment. Mice were injected
once daily at approximately the same time and monitored closely for any signs of distress or
discomfort.
Behavioral tests
All behavioral tests were conducted as per our previously-published studies [12].
Forced swim test. To assess the effects of CVS on learned helplessness, a depressive
behavior measure, the forced swim test was used. Mice were individually placed in a glass cyl-
inder (15.5cm diameter) that contained 10cm-deep temperature-controlled water (23–25 ˚C)
for a period of 5 minutes. Time immobile (i.e., floating while making only necessary move-
ments that require the animal to keep their head above the water), latency to become immobile
(time at which animal first shows signs of immobility) and time spent swimming (i.e., active,
Table 1. Group assignment and treatment numbers.
VEHICLE FLUOXETINE
CONTROL Wildtype Beh n = 10
qPCR n = 10
Beh n = 10
qPCR n = 10
STRESS Wildtype Beh n = 16
qPCR n = 9
Beh n = 14
qPCR n = 9
FGF2KO Beh n = 8
qPCR n = 4
Beh n = 9
qPCR n = 4
https://doi.org/10.1371/journal.pone.0204980.t001
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horizontal movements) were recorded on a video camera and scored by an independent
observer blind to conditions of the experiment. Immediately following the task, animals were
dried off using a paper towel and placed back in their home cage.
Sucrose consumption test. The sucrose consumption test was conducted as a measure of
anhedonia in the mice. Mice were habituated to a 1% sucrose solution for a 48-hour period fol-
lowed by overnight water deprivation. For the test, the sucrose bottle was given back for
1-hour and bottles were weighed before and after the test. Normal ad libitum access to food
was maintained throughout both habituation and testing periods. Access to water bottles
resumed immediately after the test. All solutions were made fresh each day. Mice remained
single housed throughout the process. The test was conducted in the final week (5) of the
experiment. Results from two mice were omitted from the final analysis due to spillage of the
sucrose solution prior to post-measurement.
Elevated plus maze. The elevated plus maze was used to measure anxiety and exploratory
behaviors. The dimensions of the open arms are 30 x 5cm, with two enclosed with 25cm walls,
Fig 1. Fluoxetine reverses CVS-induced depressive behavior in WT but not FGF2KO mice. (A) Experimental
timeline. (B) Graphical representation of the time spent immobile in the forced swim test. (C) Graphical
representation of the latency to immobility in the forced swim test. Bars represent means ± standard error of the mean,
data points reflect individual scores. Asterisks denote significant differences from all other groups.
https://doi.org/10.1371/journal.pone.0204980.g001
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and elevated 30cm from the floor, the room was brightly lit at 650 lux. The mouse was then
recorded exploring the maze for a total of five minutes and tracked using AnyMaze Video
Tracking System.
Open field test. A second measure of anxiety behaviour included was the open field test.
Mice were placed in the corner of a brightly lit (650 lux) box (50 x 50cm x 35cm) and video-
taped with AnyMaze Video Tracking System for 5 minutes. Time spent in the pre-defined
zones (periphery and center) was recorded. Anxiety and exploratory behaviors were measured
and included the amount of time an animal spent in the center or peripheral zone, as well as
general measures of motor activity.
Emotionality score. The emotionality score was derived as previously described in Guil-
loux (2011) [24]. Z scores were calculated for each test and normalized for locomotor behavior,
Table 2. Chronic variable stress schedule.
DAY STRESSORS DURATION
1 Cage tilt, wet bedding 4hrs, overnight
2 Restraint, lights on 15min, overnight
3 Odour, Swim 5hrs, 10min
4 Cage tilt, empty cage 2hrs, overnight
5 Wet bedding, lights on 4hrs, overnight
6 Restraint, odour 15min, 4hrs
7 Cage tilt, lights on 5hrs, overnight
8 Odour, empty cage 3hrs, overnight
9 Restraint, cage tilt 15min, 3hrs
10 Swim, lights on 10min, overnight
11 Odour, wet bedding 3hrs, overnight
12 Cage tilt, empty cage 4hrs, overnight
13 Cage tilt, lights on 5hrs, overnight
14 Restraint, odour 15min, 4hrs
15 Swim, wet bedding 10min, overnight
16 Cage tilt, empty cage 3hrs, overnight
17 Restraint, odour 15min, 5hrs
18 Swim, lights on 10min, overnight
19 Wet bedding, odour 3hrs, 3hrs
20 Cage tilt, empty cage 3hrs, overnight
21 Restraint, lights on 15min, overnight
22 Cage tilt, odour 3hrs, 4hrs
23 Wet bedding, empty cage 3hrs, overnight
24 Restraint, wet bedding 15min, 4hrs
25 Odour, lights on 4hrs, overnight
26 Cage tilt, odour 3hrs, 3hrs
27 Wet bedding, restraint 4hrs, 15min
28 Odour, empty cage 5hrs, overnight
29 Cage tilt, wet bedding 4hrs, 3hrs
30 Restraint, lights on 15min, overnight
31 Cage tilt, wet bedding 3hrs, 4hrs
32 Odour, lights on 4hrs, overnight
33 Sucrose Consumption (1hr); Restraint, cage tilt 15min, 4hrs
34 Behavior Testing OF, EPM -
35 Behavior Testing FST -
https://doi.org/10.1371/journal.pone.0204980.t002
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as appropriate.
Z score OF ¼
X  m
s
  
TimeCenter þ X  m
s
  
Proportion Peripheral Distance
2
Z score EPM ¼
X  m
s
  
TimeOpenþ X  m
s
  
Proportion Closed Distance
2
Z score FST ¼
X   m
s
 
TIme Immobile
Emotionality score ¼
ZscoreOF þ ZscoreEPM þ ZscoreFST
3
Animal sacrifice and quantitative real time PCR
One day following completion of the experiment mice were decapitated and a subset of brains
were collected, flash frozen and stored at -80˚C until use. Briefly, the hippocampus was dis-
sected and RNA was extracted using the STRATAGENE RNA isolation kit (Agilent). Quanti-
tative real time PCR was conducted as previously described [12]. Reverse transcription was
carried out using Superscript III (Invitrogen) and GR and FGF2 levels were assessed using
TAQMAN assays (Life Technologies; Assay ID: Mm00433832_m1 Gene Symbol: NR3C1;
Assay ID: Mm01285715_m1 Gene Symbol: Fgf2) as per the manufacturer’s instructions. All
assays were conducted and analyzed using the Applied Biosystems 7500 machine and proprie-
tary software set to detect TAQMAN probes/assays.
Statistical analyses
All data were analyzed using IBM SPSS Statistics Data Editor (Version 20). Analysis of vari-
ance was conducted with genotype (WT vs. FGF2KO), condition (control vs. stress) and treat-
ment (vehicle vs. fluoxetine) as independent variables. Because this model is unbalanced in its
design, we applied a more conservative alpha level to reduce the likelihood of type 1 errors,
thus probability values were considered significant when p 0.01. If the overall model was sig-
nificant then ANOVAs were followed by post-hoc t-test comparisons with Bonferonni correc-
tion for non-orthogonal tests; t-tests were considered significant when p 0.05.
Results
Chronic fluoxetine treatment does not reverse the effects of CVS on
depressive-like behavior in FGF2KO mice
In order to assess the effects of FGF2 gene deletion on the ability of fluoxetine to decrease
depressive-like behaviors in WT and FGF2KO mice, we conducted a pilot study comparing
WT and FGF2KO mice treated with either chronic vehicle or fluoxetine. Results from both the
forced swim test and the sucrose consumption test showed no effect of fluoxetine in either WT
or FGF2KO mice (data not shown). Because these were experimentally naïve animals and pre-
vious studies in mice have shown that fluoxetine decreases depressive behaviors following per-
turbations such as stress [25], we hypothesized that exposure to chronic stress would induce
depressive behaviors and therefore increase sensitivity to fluoxetine’s anti-depressant effects.
Fibroblast growth factor 2 and fluoxetine
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Therefore, in a subsequent study to examine the effects of FGF2 gene deletion on fluoxe-
tine’s ability to decrease depressive-like behaviors, WT and FGF2KO mice were exposed to
CVS and tested on the forced swim and sucrose consumption tests. In addition, we had non-
stressed WT mice that were similarly injected with vehicle or fluoxetine. Results from the
forced swim test showed a significant overall model both for total immobility time (F(5,66) =
29.26, p<0.0001) (Fig 1B) and latency to immobility (F(5,66) = 28.14, p<0.0001) (Fig 1C). Com-
parisons of simple effects revealed that all stress groups had a significant increase in immobility
from vehicle-treated, WT controls (p<0.01) (Fig 1B). In addition, WT, stressed mice that were
treated with fluoxetine showed a significant decrease in immobility from their vehicle-treated
WT stressed counterparts (p<0.01). FGF2KO mice showed no response to fluoxetine
(p>0.05) (Fig 1B). Similarly, comparisons of simple effects revealed that all stressed groups
had a significant decrease in the latency to immobility as compared to non-stressed controls
(p<0.01) (Fig 1C). WT, stressed mice treated with fluoxetine showed a trend for an increase in
the latency to immobility (p = 0.06). FGF2KO mice did not respond to fluoxetine treatment
(p>0.05) (Fig 1C).
Results from the sucrose consumption test, a measure of anhedonia, showed no significant
differences in sucrose consumption (baseline), water consumption (baseline) or sucrose/water
consumption (data not shown). In addition, no differences in weight were observed across
groups (data not shown) (p>0.05 for all comparisons).
Chronic fluoxetine treatment does not reverse the effects of CVS on
anxiety-like behavior in FGF2KO mice
To examine the effects of FGF2 gene deletion on fluoxetine’s ability to decrease anxiety-like
behaviors, mice were also tested on the elevated plus maze and open field tests. Results from
the elevated plus maze showed a significant overall model for time spent in the open arms
(F(5,66) = 10.53, p<0.0001) (Fig 2A), distance travelled in open arms (F(5,66) = 5.03, p<0.001)
(data not shown), and distance in open arms/total distance travelled (F = 3.8(5,66), p<0.01)
(Fig 2B). Simple effects showed that control mice spent more time in the open arms than all
stress groups. WT stressed mice treated with fluoxetine showed an increase in the proportion
of distance travelled in open arms as compared to vehicle-treated counterparts. Interestingly,
no effect of fluoxetine was again observed in FGF2KOs. Finally, the overall model for total
distance travelled was not significant, suggesting no changes in locomotor activity overall
(F(5,66) = 1.12, p>0.01) between groups (Fig 2C).
Results from the open field test showed a significant overall model for time in center zone
(F(5,66) = 9.7, p<0.0001) (Fig 3A) and latency to enter the center zone (F(5,66) = 4.12, p = 0.003)
(Fig 3B). Post-hoc tests showed that all stressed groups spent less time in the center and had a
longer latency to enter the center. Moreover, FGF2KO mice showed a further decrease in time
in the center and a trend for a longer latency (p = 0.07) as compared to their WT, stressed
counterparts, suggesting an additive effect of stress and FGF2 gene deletion. No effects of flu-
oxetine were observed on any measure of the open field test.
Chronic fluoxetine treatment increases FGF2, but not GR gene expression
levels in wild-type mice only
Because we have previously shown that the effects of FGF2 administration on anxiety behavior
are mediated through FGF2-induced GR upregulation [12], we quantified hippocampal levels
of FGF2 and GR using q-RT-PCR. Results showed a significant overall model for GR as well as
main effects of both stress and genotype (p<0.01 for all) such that stressed mice showed lower
Fibroblast growth factor 2 and fluoxetine
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GR levels than non-stressed mice and FGF2KO mice showed a further decrease in GR
(Fig 4A). No effects of fluoxetine were observed on GR (Fig 4A).
FGF2 levels did not change overall (p = 0.04), however there were significant main effect of
stress (p<0.01) such that all stressed groups had decreased levels of FGF2 from non-stressed
controls (Fig 4B). Because it has been previously shown that acute administration of fluoxetine
increases hippocampal FGF2 [26], we compared FGF2 levels of Vehicle treated, stressed WT
Fig 2. Fluoxetine reverses CVS-induced anxiety behavior in WT but not FGF2KO mice on the elevated plus maze.
(A) Graphical representation of the total time spent in the open arms of the EPM. (B) Graphical representation of the
distance travelled in the open arms relative to the total distance travelled in the EPM. (C) Total distance travelled over
the entire EPM. Bars represent means ± standard error of the mean, data points reflect individual scores.
https://doi.org/10.1371/journal.pone.0204980.g002
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mice to their fluoxetine treated counterparts and found a trend (p = 0.06) for an increase in
FGF2 levels with fluoxetine treatment.
In order to conceptualize the overall anxiety and depressive phenotype, we included a total
“emotionality score” that we have previously employed and was first described by the Sibille
laboratory [24, 27]; a significant increase in emotionality was induced by stress, which was
reduced in fluoxetine-treated stressed WT mice (Fig 5A). No effect of fluoxetine was seen in
FGF2KOs.
Because behavior and gene expression levels were conducted in the same mice, we corre-
lated both GR and FGF2 gene expression levels to our behavioral measures (See Table 3).
Fig 3. Fluoxetine has no effect on CVS-induced anxiety behavior in mice on the open field test. (A) Graphical
representation of the time in the centre in the open field test. (B) Graphical representation of latency to enter the centre
zone in the open field test. Bars represent means ± standard error of the mean, data points reflect individual scores.
Asterisks denote significant differences from all other groups.
https://doi.org/10.1371/journal.pone.0204980.g003
Fibroblast growth factor 2 and fluoxetine
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Significant correlations were observed between GR levels and measures of the open field, ele-
vated plus maze and forced swim test (see Table 3 for specific correlations). FGF2 levels were
also significantly correlated to the elevated plus maze and forced swim tests, however no signif-
icant relationship was observed between FGF2 and the open field test (See Table 3). GR levels
were also significantly correlated to the emotionality score (r = -0.409; p<0.01) (Fig 5B). Simi-
larly, FGF2 levels were correlated with the emotionality score (r = -0.302; p<0.05) (Fig 5C).
Discussion
The current study sought to ascertain whether there is a causal role for the FGF2 gene in medi-
ating the therapeutic effects of the SSRI fluoxetine in mice exposed to CVS. No effects of fluox-
etine were observed in naïve mice, however, fluoxetine predictably reversed many of the
stress-induced depressive and anxiety behaviors in WT mice. Remarkably, FGF2KO mice did
Fig 4. CVS decreases hippocampal GR and FGF2 expression levels. (A) Graphical representation of the GR fold
change. (B) Graphical representation of the FGF2 fold change. Bars represent means ± standard error of the mean,
data points reflect individual scores.
https://doi.org/10.1371/journal.pone.0204980.g004
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not show any reversal of stress-induced behaviors with fluoxetine, suggesting that FGF2 is
necessary for the therapeutic effects of fluoxetine. These findings corroborate studies in
humans with major depressive disorder that showed that variants of the FGF2 gene can predict
efficacy of SSRI treatment and suggest an important role for FGF2 in the mechanisms of anti-
depressant action [23]. While the anti-depressant and anxiolytic effects of FGF2 have been pre-
viously documented in several rodent models, the current study would suggest that FGF2 not
only has antidepressant/anxiolytic properties, but that it is necessary for fluoxetine’s therapeu-
tic effects.
Interestingly, somewhat discrepant results were observed on measures of anxiety behavior,
as expected, fluoxetine decreased anxiety in WT mice on the elevated plus maze, however
Fig 5. Fluoxetine reverses the CVS-induced increase in the emotionality index in WT but not FGF2KO mice. (A)
Graphical representation of the emotionality index. (B) Correlation scatter plot showing the relationship between GR
expression levels (fold change) and the total emotionality index. (C) Correlation scatter plot showing the relationship
between the FGF2 expression levels (fold change) and the total emotionality index. Bars represent means ± standard
error of the mean, data points reflect individual scores.
https://doi.org/10.1371/journal.pone.0204980.g005
Fibroblast growth factor 2 and fluoxetine
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fluoxetine had no significant effect on anxiety in WT mice in the open field test. Although
both the open field and elevated plus maze are used as measures of anxiety, discrepancies
between the findings of these two tests have been previously reported [28]. Moreover, previous
reports have shown strain differences that are consistent with our results here in C57/Bl6 mice
[29]. The reason for the dissociation between these two tests remains unknown, nevertheless,
FGF2 gene deletion did not show any responses to fluoxetine on either of these tests, suggest-
ing that regardless of the behavioral output measured, FGF2 is necessary for the effects of
fluoxetine.
Fluoxetine decreased the total emotionality score in CVS-exposed mice as expected. How-
ever, a paradoxical effect of fluoxetine was also noted in non-stressed, wild-type control mice,
where fluoxetine actually increased the emotionality score. It is not clear if this is a genuine
increase in emotionality; given the limited number of studies that have included this index, it
is not possible to examine if this is consistent. However, because locomotor activity is a com-
ponent in generating the emotionality score, it is possible that fluoxetine-induced locomotor
activity changes contributed to the change in emotionality index in this group. Further studies
will be needed to determine if this is a consistent effect or a limitation in this index.
We have previously shown that the effects of FGF2 administration on anxiety behavior
were mediated through FGF2’s upregulation of hippocampal glucocorticoid receptor expres-
sion [12]. In the current study, glucocorticoid receptor expression was similarly decreased in
FGF2KO mice, however, expression did not change with fluoxetine administration in WT
mice, suggesting that changes in expression of hippocampal glucocorticoid receptors cannot
be the FGF2-dependant mechanism of action by which fluoxetine reverses stress-induced
behavioral changes, at least at the time-point examined. Importantly, however, this does not
preclude the possibility that the reduction in GR caused by FGF2 gene deletion is responsible
for the lack of response to fluoxetine in FGF2KO mice. Interestingly, it appears as if GR levels
show an additive response to stress and FGF2 gene deletion and indeed, GR levels were signifi-
cantly correlated with all behavioral tests. Although we have previously shown that GR is caus-
ally implicated in the anxiolytic effects of FGF2 [12], whether GR is causally related to the
effects of chronic stress in the current study remains to be determined.
Although FGF2 has been widely implicated in anxiety and depressive-like behavior, FGF2
levels in response to the CVS model currently employed have not been previously measured.
Interestingly, hippocampal FGF2 levels decrease in WT mice following chronic stress to simi-
lar levels observed in FGF2KO mice, and levels of FGF2 were negatively correlated with most
Table 3. Pearson correlations between GR and FGF2 fold change with depressive and anxiety-like behaviors.
1 2 3 4 5 6 7
1. Time Centre (OF)
2. Centre Distance (OF) 0.69a
3. Time Open (EPM) 0.45 a 0.46 a
4. Open Distance (EPM) 0.19 0.38 a 0.77 a
5. Time Immobile (FST) -0.54 a -0.30 b -0.43 a -0.28
6. Latency to Immobility (FST) 0.55 a 0.33 a 0.59 a 0.31 b -0.80 a
7. GR Fold Change 0.51 a 0.36 b 0.42 a 0.26 -0.39 a 0.41 a
8. FGF2 Fold Change 0.24 0.26 0.35 b 0.10 -0.33 b 0.37 b 0.36b
a Where p< 0.001 (2-tailed)
b Where p< 0.05 (2-tailed)
https://doi.org/10.1371/journal.pone.0204980.t003
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of the behavioral measures tested, further strengthening the relationship between hippocampal
FGF2 and anxiety and depressive-like behavior.
There are many known effects of FGF2 in the adult brain which are related to neuroplastic
events. Like FGF2, there are several other growth factors that are not downregulated post-
development and continue to be expressed in the adult brain, such as BDNF and VEGF.
Importantly, these factors also play critical roles in regulating neuroplasticity and have been
implicated in anxiety and depressive-like behaviors and their treatment [30]. While it is not
clear how each of these growth factors uniquely contributes to modulating depressive and anx-
iety-like behaviors, unlike BDNF and VEGF, FGF2 is largely produced by astroglial cells, and
the effects of FGF2 on neuroplasticity are typically mediated through astroglial cells [31]. This
suggests that FGF2’s unique contribution to the pathology and treatment of anxiety and
depressive-like behaviors may be better understood by examining the cells that are targeted,
astroglia. Interestingly, a large body of evidence has begun to implicate astroglia in depressive/
anxiety phenotypes [24, 32–38], including work demonstrating that an injection of a gliatoxin
and not a neurotoxin into the prefrontal cortex, induces a phenotype comparable to that
observed following CVS [39]. It is therefore possible that the FGF2-mediated effects of fluoxe-
tine that we have observed here are related to FGF2-induced astroglial changes rather than
changes in HPA activity. Indeed, chronic fluoxetine treatment has been demonstrated to
increase the number of hippocampal astroglial cells as marked by S100B and GFAP, increase
the production of anti-inflammatory cytokines and reverse stress-induced decreases in astro-
glial specific proteins associated with gap-junction connectivity [33, 40].
Whether astroglia, astroglial functions, or HPA changes are the downstream target of FGF2
mediated changes induced by fluoxetine remains to be determined, however, the current study
reaffirms the potential of FGF2 as a novel therapeutic target in the treatment of depression and
anxiety disorders.
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